PT-141
Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
The primary literature on this compound includes Diamond et al., J Sex Med (2006). The references below link directly to the published record.
Every lot is synthesized in the USA, verified by HPLC, and ships with its Certificate of Analysis. It is supplied strictly for laboratory research use.
Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.
Published research
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsKingsberg SA, et al. Obstet Gynecol. 2019.PubMed →
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderSimon JA, et al. Obstet Gynecol. 2019.PubMed →
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionDiamond LE, et al. Int J Impot Res. 2004.PubMed →
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to ViagraRosen RC, et al. Int J Impot Res. 2004.PubMed →